Bionomics Limited has been all-in on its allosteric ion channel modulator BNC210 in neuropsychiatric indications for years and is bullish about moving forward now that the drug met the primary endpoint in a Phase IIb trial of 212 patients with post-traumatic stress disorder (PTSD). CEO Spyros Papapetropoulos told a same-day call that the company intends to discuss a regulatory pathway with the US Food and Drug Administration and thinks it could have a potential blockbuster on its hands.
Based in both Adelaide, Australia, and Cambridge, MA, Bionomics got an enthusiastic response from investors as its stock price soared on 28 September on the positive data, finishing up 244%...
Calling 2023 a “transformational” year for Bionomics, Papapetropoulos told the call that BNC210 showed a treatment effect greater than what was seen in clinical trials with the two established SSRIs...